BioSpace News Archive

Santhera Pharmaceuticals and ReveraGen BioPharma, Inc announce presentations of the positive topline results from the pivotal VISION-DMD study and new safety analyses from long-term treatment with vamorolone at the forthcomingWorld Muscle Society 2021 Virtual Annual Conferenceand The American Society for Bone and Mineral Research 2021 Annual Meeting.

Nicox SA, an international ophthalmology company, announced the results from its Mississippi Phase 2b clinical trial evaluating once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, against placebo in patients with acute exacerbations of blepharitis.

The shareholders of Biovica International AB, reg. no. 556774-6150, are hereby invited to the extra general meeting on Tuesday 12 October 2021.

Aryballe, the pioneer in digital olfaction, announced it has appointed Pierre Chauvineau as its new Chairman of the Board.

RaySearch Laboratories AB announces that the National Cancer Centre Singapore has placed an order for RayStation®* as the treatment planning system for its new proton therapy center currently under construction and scheduled for completion by 2022.

CB Scientific. Inc. announced that it has hired and enter into a consultant services agreement with the Dorchester Group LLC, and its President Robert H. Hesse, to assist and advise the company in its current financing strategies, as well as marketing initiatives in the US and SE Asia.

Annexon, Inc. announced that Douglas Love, Esq., President & Chief Executive Officer, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 12:40 p.m. ET.

Clene Inc. announced the launch of a second U.S. Food and Drug Administration expanded access program with CNM-Au8 for people living with amyotrophic lateral sclerosis.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced it has expanded its research collaboration with Columbia University.

Big Cypress Acquisition Corp announced that it will hold a Special Meeting of stockholders to, among other matters, allow its stockholders to approve the proposed business combination with SAB Biotherapeutics, Inc..